• About us
• Contact

Advertisement

Organisation › Details

Cellectis S.A. (Euronext Growth: ALCLS, Nasdaq: CLLS)

Cellectis is a pioneer in the field of genome engineering. The company designs and markets innovative tools – meganucleases. These molecular scissors enable targeted modifications to DNA, with applications in the research, biomanufacturing, agrobiotechnology and therapeutic sectors. To date, Cellectis has formed over 20 academic research partnerships and has established more than 50 agreements with pharmaceutical laboratories, seed producers and biotech companies across the world. The company holds exclusive rights to a portfolio of over 260 patents granted or pending. Since 2007, Cellectis has been listed on the NYSE-Euronext Alternext market (code: ALCLS) in Paris and has secured over €70 million in funding since inception. *

 

	Start	1999-01-01 established
	Group	Cellectis (Group)
	Industry	genome editing (gene editing)
	Industry 2	TALEN® technology (Transcription Activator-Like Effector Nuclease)
	Person	Choulika, André (Cellectis 200701 CEO + Co-Founder)
	Person 2	Dutang, Eric (Cellectis 2016– CFO joined 201505)
	Region	Romainville
	Country	France
	Street	8 Rue de la Croix Jarry
	City	75013 Paris
	Tel	+33-1-8169-1600
		Address record changed: 2024-01-05
Basic data	Employees	D: 101 to 500 (2019-12-31)
	Currency	USD
	Annual sales	22,990,000 (income, total, consolidated (2019) 2019-12-31)
	Profit	-115,212,000 (2019-12-31)
	Cash	340,522,000 (2019-12-31)
		* Document for »About Section«:
		Record changed: 2024-02-12

Advertisement

More documents for Cellectis (Group)

• [1] Cellectis S.A.. (12/29/22). "Press Release: Mayflower Bioventures Launches Its First Spin-Out, Primera Therapeutics, in Strategic Collaboration with Cellectis to Develop a Gene Editing Platform to Treat Mitochondrial Diseases". New York, NY....
• [2] Cellectis S.A.. (12/28/22). "Press Release: Cellectis Secures a €40 Million Credit Facility from the European Investment Bank to Support its Research, Development and Innovation Activities". Paris....
• [3] Biovian Oy. (9/6/22). "Press Release: Biovian Appoints Its First US-based Business Development Manager"....
• [4] Cellectis S.A.. (2/10/22). "Press Release: Cellectis Appoints Bing Wang, PhD, MBA as Chief Financial Officer". New York, NY....
• [5] Metagenomi Inc.. (7/28/21). "Press Release: Metagenomi Appoints Simon Harnest as Chief Investment Officer". Emeryville, CA....
• [6] Cellectis S.A.. (2/16/21). "Press Release: Cytovia Therapeutics and Cellectis Partner to Develop TALEN Gene-Edited iPSC-Derived Natural Killer Cells". Cambridge, MA & New York, NY....
• [7] Sirion Biotech GmbH. (1/7/21). "Press Release: Sirion Biotech GmbH Licensed Its LentiBoost Transduction Technology to Cellectis". Munich & Cambridge, MA....
• [8] Cellectis S.A.. (12/15/20). "Press Release: Cellectis Announces Withdrawal of Follow-On Offering". New York, NY....
• [9] Cellectis S.A.. (12/14/20). "Press Release: Cellectis Announces Launch of Follow-On Offering". New York, NY....
• [10] Cellectis S.A.. (7/6/20). "Press Release: Cellectis Reports Clinical Hold Placed on MELANI-01 Study". New York, NY....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2025. Made in Germany.